BidaskClub upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a sell rating to a hold rating in a report published on Wednesday morning, BidAskClub reports.

Several other research analysts have also commented on the stock. HC Wainwright began coverage on shares of Collegium Pharmaceutical in a research note on Friday, May 3rd. They set a buy rating and a $23.00 price objective for the company. ValuEngine lowered shares of Collegium Pharmaceutical from a hold rating to a sell rating in a research note on Wednesday, May 1st. Cantor Fitzgerald set a $35.00 price objective on shares of Collegium Pharmaceutical and gave the stock a buy rating in a research note on Friday, April 26th. Zacks Investment Research lowered shares of Collegium Pharmaceutical from a buy rating to a hold rating in a research note on Wednesday, April 24th. Finally, Janney Montgomery Scott began coverage on shares of Collegium Pharmaceutical in a research note on Friday, April 12th. They set a buy rating and a $29.00 price objective for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $27.29.

NASDAQ COLL opened at $12.05 on Wednesday. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.24 and a quick ratio of 1.19. The company has a market cap of $407.32 million, a P/E ratio of -10.13 and a beta of 0.47. Collegium Pharmaceutical has a 52 week low of $10.55 and a 52 week high of $28.91.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.01. The firm had revenue of $74.52 million during the quarter, compared to analyst estimates of $70.10 million. Collegium Pharmaceutical had a negative net margin of 10.36% and a negative return on equity of 30.87%. Research analysts forecast that Collegium Pharmaceutical will post -0.4 earnings per share for the current fiscal year.

In other Collegium Pharmaceutical news, CEO Joseph Ciaffoni sold 7,436 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $11.59, for a total transaction of $86,183.24. Following the sale, the chief executive officer now owns 190,755 shares of the company’s stock, valued at approximately $2,210,850.45. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Michael Thomas Heffernan sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $12.84, for a total transaction of $321,000.00. Following the sale, the director now directly owns 188,586 shares in the company, valued at approximately $2,421,444.24. The disclosure for this sale can be found here. In the last three months, insiders have sold 63,287 shares of company stock worth $851,837. 8.08% of the stock is owned by insiders.

Large investors have recently added to or reduced their stakes in the business. State Board of Administration of Florida Retirement System grew its position in Collegium Pharmaceutical by 4.8% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 14,359 shares of the specialty pharmaceutical company’s stock worth $247,000 after purchasing an additional 655 shares during the last quarter. Monarch Partners Asset Management LLC grew its position in Collegium Pharmaceutical by 19.2% during the 4th quarter. Monarch Partners Asset Management LLC now owns 33,770 shares of the specialty pharmaceutical company’s stock worth $580,000 after purchasing an additional 5,430 shares during the last quarter. Virginia Retirement Systems ET AL purchased a new stake in Collegium Pharmaceutical during the 1st quarter worth approximately $160,000. BlackRock Inc. grew its position in Collegium Pharmaceutical by 8.7% during the 4th quarter. BlackRock Inc. now owns 2,619,718 shares of the specialty pharmaceutical company’s stock worth $44,980,000 after purchasing an additional 210,145 shares during the last quarter. Finally, Martingale Asset Management L P purchased a new stake in Collegium Pharmaceutical during the 4th quarter worth approximately $994,000. 94.15% of the stock is currently owned by institutional investors.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.

Recommended Story: Earnings Per Share (EPS)

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.